lenalidomide (Revlimid)

Following a re-submission

lenalidomide (Revlimid®) is accepted for restricted use within NHS Scotland.

Licensed indication under review: in combination with dexamethasone, for the treatment of multiple myeloma patients who have received at least one prior therapy.

SMC restriction: use in patients who have received at least two prior lines of therapy. Lenalidomide plus dexamethasone significantly increased the time to progression compared with dexamethasone alone in multiple myeloma patients who had been treated with at least one prior therapy.

The health economic case was demonstrated only for a sub-population of patients within the licensed indication.

Taking into account the orphan drug status of lenalidomide and the substantial survival benefit it appears to offer SMC concluded that the economic case was demonstrated.